Princeton BioMeditech (PBM) and C2Sense have received funding to accelerate the commercialisation of a highly sensitive, fluorescent version of PBM’s Status Covid-19/Flu A&B antigen test.
Phase 1 funding has been granted by the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx) Tech High Performance programme.
The financing will be utilised for the conversion of PBM’s colourimetric OTC Covid-19/Flu A&B multiplexed lateral flow assay into a fluorescent immunoassay.
A portion of the funds will be also used to advance the development of C2Sense’s Halo – a cost-effective and highly sensitive digitally connected universal assay reader.
PBM vice-president Roger Kang said: “PBM is looking forward to collaborating with C2Sense to increase the sensitivity of our widely adopted POC multiplex Covid-19/Flu A&B assay and bring it to consumers.”
The fluorescent version of PBM’s Status Covid-19/Flu A&B antigen test will be used along with the Halo diagnostic reader.
Halo is designed with a user-friendly interface offering an intuitive app-guided journey for its users. With its low-power design, it ensures reliable digital outputs for colourimetric and fluorescently labelled assays.
C2Sense CEO Dr Jason Cox said: “The NIH RADx programme has become the gold standard for the development and deployment of innovative diagnostic solutions and this award further validates the capabilities of our Halo platform.
“We feel that there is an immediate need for highly accurate, rapid at-home testing that produces real-time digital results and that this collaboration with PBM is progress towards that solution.”
Launched in April 2020, the NIH RADx initiative aims to accelerate the development, commercialisation and deployment of advanced technologies for Covid-19 detection.
The third funding announcement under the RADx Tech programme focuses on expediting the implementation of user-friendly tests that minimise the need for repeated testing and adapt seamlessly to emerging variants.